

Priority Issue 1

# Fulfill Unmet Medical Needs

|  |   |
|--|---|
| <p>Target for 2030</p>                 | <p>Develop and disseminate new treatments based on regenerative medicine and cell therapy.</p>  |
|  | <p>The Fujifilm Group is striving forward in the development and dissemination of new therapies for unmet medical needs, where effective treatment is still to be found. Fujifilm possesses the highly functional material synthetic technologies and engineering skills that we have gained through our photographic film development and production, including advanced nano dispersion technology, analysis technology, and production engineering technologies. We are actively seeking synergetic collaborations with business partners who also possess superior technologies, in order to develop new solutions in regenerative medicine and cell therapy and improve accessibility to such advanced treatments.</p>   |
| <p>Outline of Activities in FY2017</p> | <p><b>[Target] Develop new treatment solutions</b><br/>                 (1) Regenerative medicine, (2) Anti-cancer measures, (3) Infectious disease treatment</p> <ul style="list-style-type: none"> <li>① Submitted application to the Ministry of Health, Labour and Welfare for approval on a partial usage change of Autologous Cultured Epidermis JACE® to expand applications for epidermolysis bullosa treatment.</li> <li>② Started U.S. Phase I clinical trials of the anti-cancer agent FF-10832 for advanced solid tumors. (Development of a liposome drug that will be selectively delivered to the tumor, enhancing the pharmacological efficacy.)</li> <li>② Started Phase II clinical trials in Japan on therapeutic radiopharmaceutical F-1614 targeted at refractory melanocytoma.</li> <li>② Started U.S. Phase I clinical trials of anti-cancer agent FF-10101 targeted at recurrent and/or refractory acute myeloid leukemia.</li> <li>② Launched a PET radiopharmaceutical Fludeoxyglucose (18F) intravenous injection.</li> <li>③ Received the Prize for Science and Technology under a Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology FY2018 for development of an influenza antiviral drug with a new mode of antiviral action for pandemic prevention.</li> <li>③ Started Phase III clinical trials of Favipiravir, a broad-spectrum antiviral agent targeted at severe fever with thrombocytopenia syndrome (SFTS).</li> </ul> <p><b>[Target] Improve accessibility to new treatment solutions</b> (4) Contribution through contract development and manufacturing, (5) Contribution through development and dissemination of products that support advanced medicine)</p> <ul style="list-style-type: none"> <li>④ Further enhanced contract development and manufacturing business of biopharmaceuticals* and started operations at a new manufacturing building in the US Texas site.</li> <li>④ Built a new factory aiming at stable supplies of our high quality and reliability liposome drug utilizing our exclusive technologies.</li> <li>⑤ Acquired Irvine Scientific Sales Company and IS Japan, leading companies in the area of cell culture media.</li> </ul> <p>* Biopharmaceuticals: Pharmaceutical products utilizing biological particles, such as proteins, that provide effects unachievable by conventional chemically synthesized small-molecule drugs. Such biopharmaceuticals include insulin, vaccines, and antibody drugs. Antibody drugs utilize antibodies, proteins used by the immune system to protect our bodies from infectious or abnormal organisms, such as viruses and cancer cells, by recognizing them selectively.</p> |
| <p>Future Activities and Targets</p>   | <ul style="list-style-type: none"> <li>● Introduce our regenerative medicine products to the market, expand their application to treatment, and improve contract manufacturing for these products.</li> <li>● Accelerate development of our new drug pipeline.</li> <li>● Expand contract manufacturing for biopharmaceuticals.</li> <li>● Develop and disseminate cell culture or other production technologies that support advanced biomedical treatment (gene therapy, etc.).</li> </ul>  |



## ● Development and Dissemination of Cell Culture Media to Contribute to Regenerative Medicine and Cell Therapies

Cell culture media are critical technology and materials used in the research, development, and production of regenerative medicine products and biopharmaceuticals. It is said that the quality of the cell culture media determines the quality and medical efficacy of the cell culture. As social attention is increasingly drawn to biopharmaceuticals and cell therapies as new approaches to medical treatment, high quality cell culture media are also in demand. The Fujifilm Group is accelerating its R&D in the field of regenerative medicine in

### ▼ Three Key Elements Required in Regenerative Medicine

\* Below is an explanation of these three elements using the analogy of "rice cultivation"

